USP and the South Korea Food and Drug Administration (KFDA) have signed a memorandum of understanding (MoU) that seeks to identify areas of collaboration between the organizations, raise awareness of the importance of the quality and safety of medicines, and identify areas of mutual interest.
KFDA Commissioner Hee-Sung Lee and USP CEO Roger Williams signed the MoU during a ceremony at KFDA headquarters in Seoul, South Korea, in mid-April.
“The global pharmaceutical community is inextricably connected, making arrangements like this important to both countries, the region, and the world,” Williams emphasized. “KFDA and USP have already engaged in a number of mutually beneficial activities, providing each organization with in-depth knowledge of how the other operates. This agreement will allow for further opportunities for collaboration that will benefit the people of both countries by advancing the mutual desire for universally trustworthy medicines.”
KFDA’s Lee commented that the MOU between KFDA and USP “will serve as an excellent opportunity to share our contributions in enhancing pharmaceutical quality and the important role we play to secure the safety and quality of medicines. I hope to exchange our experience and establish mutual trust to further facilitate the pharmaceutical trade between the two countries.”
Potential areas of collaboration identified in the MoU include: ● annual scientific meetings, workshops, seminars and forums to discuss the establishment of relevant chemical, biologics and herbal medicine standards and specifications ● collaborative studies on the development, production, storage and distribution of reference standards ● joint education and training programs on compendia and allied topics and execution of compendial procedures, and ● the exchange of scientific experts and other staff for mutual understanding of compendial procedures and quality control of reference standards.
Also on the international front, USP is planning to extend its effort to help Africa better assure the quality and integrity of its pharmaceutical supply with a new USP training/laboratory center slated to be located in Ghana (IPQ “The News in Depth, April 13, 2012).
The new USP Sub-Saharan Africa Center for Pharmaceutical Advancement and Training (CePAT) will serve the region with an integrated platform for training, education, consulting and laboratory capabilities, and will offer a systematic approach to the quality control of medicines.[/membership]